GRAFT POLYMER UK LS -001
Research GRAFT POLYMER UK LS -001 (J4I) on Bullrun: market cap EUR 10.21M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerJ4I
- ExchangeF
- CountryUnited Kingdom
- SectorIndustrials
- IndustrySpecialty Industrial Machinery
- CurrencyEUR
- Market capEUR 10.21M
- Financial periodFY2024
- RevenueGBP 0
- Revenue growth-100.0%
- Net income-GBP 1.59M
- Free cash flow-GBP 1.13M
Valuation Snapshot
latest market cap is EUR 10.21M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2024 | GBP 0 | -GBP 1.59M | -GBP 1.13M | n/a | n/a | GBP 757.00K | GBP 0 | GBP 3.08M |
| FY2023 | GBP 587.00K | -GBP 3.12M | -GBP 1.45M | 44.0% | n/a | GBP 155.00K | n/a | GBP 2.03M |
| FY2022 | GBP 542.00K | -GBP 2.71M | -GBP 3.08M | 55.4% | n/a | GBP 1.64M | GBP 0 | GBP 4.55M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | EUR 10.21M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About GRAFT POLYMER UK LS -001
Solvonis Therapeutics plc, a clinical-stage biopharmaceutical company, develops medicines for addiction, psychiatry, and neurology disorders. The company develops SVN-001, an NMDA receptor antagonist that is in Phase III clinical trial for the treatment of severe alcohol use disorder; and SVN-002, which has completed Phase I clinical trial to treat moderate to severe alcohol use disorder. Its pre-clinical stage product consists of SVN-114 for the treatment of post-traumatic stress disorder;
Related stock research
Other Industrials stocks
Frequently asked questions
What is GRAFT POLYMER UK LS -001's market cap?
GRAFT POLYMER UK LS -001's market capitalization is EUR 10.21M.
What does GRAFT POLYMER UK LS -001 do?
Solvonis Therapeutics plc, a clinical-stage biopharmaceutical company, develops medicines for addiction, psychiatry, and neurology disorders. The company develops SVN-001, an NMDA receptor antagonist that is in Phase III clinical trial for the treatment of severe alcohol use disorder; and SVN-002, which has completed Phase I clinical trial to treat moderate to severe alcohol use disorder. Its pre-clinical stage product consists of SVN-114 for the treatment of post-traumatic stress disorder; and SVN-015 for the treatment of stimulant use disorder.